Authors: Vidya Gaikwad, Shruti Mallya, Pankaj Salvi
Introduction: Women of reproductive age are more prone to iron deficiency anemia (IDA) due to blood loss or increased iron demand due to menstruation, pregnancy and lactation. With this background, the study aims to find the safety and efficacy of intravenous ferric carboxymaltose in the treatment of iron deficiency anemia in women who has just delivered. Materials and Methods: The present study was a Prospective interventional hospital based therapeutic trial conducted on postpartum anemic women of more than 18 years of age with HB the study period. Intravenous ferric carboxymaltose (FCM) was given to the anemic women who has just delivered. Total 500 mg/10 ml in 250 ml of 0.9% normal saline was given over 15-20 min. Results: Mean hemoglobin level before intravenous ferric carboxymaltose was 8.42 0.61 gm% while it was 10.03 0.74 gm% after treatment. Before treatment, 17(28.3) women had Hb between 7.1 to 8 gm% which was decreased to 3(5) after giving intravenous ferric carboxymaltose. There was significant rise in Hb level, Serum ferritin, MCV and MCHC after 2 weeks of treatment.(p < 0> Conclusion: We conclude from our study that Intravenous ferric carboxymaltose increses Hb levels and restores iron stores better in a shorter period of time. It also elevates serum ferritin levels. No serious adverse effects were noted and it was well tolerated by the patients. Patient compliance was better due to shorter hospital stay and single dose infusion. Keywords: Ferric Carboxymaltose, Postpartum Anemia, Intravenous Injection.
Open full article page